Effects of an herbal medication containing bee products on menopausal symptoms and cardiovascular risk markers: Results of a pilot open-uncontrolled trial

MedGenMed Medscape General Medicine

Volumn 6, Issue 4, 2004, Pages

  Georgiev, Dimiter B ^a   Metka, Marcus ^b   Huber, Jonannes C ^b   Goudev, Assen R ^c   Manassiev, Nikolai ^d  

^a Second Municipal Hospital for Obstetrics and Gynecology Sheynovo   (Bulgaria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^d The Wand Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; C REACTIVE PROTEIN; CHOLESTEROL; ENZYME; FLAVONOID; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN; LIGNAN DERIVATIVE; LOW DENSITY LIPOPROTEIN; OLIGOPEPTIDE; PHYTOESTROGEN; PHYTOSTEROL; POLLEN EXTRACT; ROYAL JELLY; TOPICAL AGENT; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BEE; BLOOD ANALYSIS; BODY WEIGHT DISORDER; BULGARIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL OBSERVATION; CLINICAL TRIAL; DATA ANALYSIS; DEPRESSION; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG ERUPTION; DRUG MECHANISM; FACE DISORDER; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GYNECOLOGY; HORMONAL THERAPY; HOSPITAL DEPARTMENT; HUMAN; IRRITABILITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OBSTETRICS; OPEN STUDY; PILOT STUDY; POSTMENOPAUSE; PROBLEM SOLVING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SELF CONCEPT; SELF ESTEEM; SELF EVALUATION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 25144476237     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its ffects on vasomotor symptoms and endometrial safety in postmenopausal women. Menopause. 2002;9:195-207.
2. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21:464-480.
3. al-Azzawi F, Wahab M. Estrogen and colon cancer: current issues. Climacteric. 2002;5:3-14.
4. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:49-57.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
6. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer s disease. Lancet. 1996;348:429-432.
7. Yaffe K, Sawwaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA. 1998;279:688-695.
8. Mulnar RA, Corman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA. 2000;283:1007-1015.
9. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
10. Adlercreutz H, Goldin BR, Gorbach SL, et al. Soybean phytoestrogen intake and cancer risk. J Nutr. 1995;125(suppl):757S-770S.
11. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol. 1996;87:897-904.
12. Adlercreutz H, Mazur W. Phytoestrogens and Western diseases. Ann Med. 1997;29:95-120.
13. Boulet MJ, Oddens BJ, Lehert P, Vemer HM, Visser A. Climacteric and menopause in seven south-east Asian countries. Maturitas. 1994;19:157-176.
14. Adlercreutz H, Fotsis T, Bannwart C, et al. Determination of urinary lignans and phytoestrogens metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem. 1986;25:791-797.
15. Wilcox G, Wahlqvist ML, Burger HG, Medley G. Oestrogenic effects of plant foods in postmenopausal women. BMJ. 1990;301:905-906.
16. Baird DD, Umbach DM, Lansdell L, et al. Dietary study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab. 1995;80:1685-1690.
17. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomised placebo-controlled crossover trial with phytoestrogens in treament of menopause in breast cancer patients. Obstet Gynecol. 2003;101:1213-1220.
18. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of the arterial inflammatory response: a new perspective. Hypertension. 1995;25:155-161.
19. Colins T. Endothelial nuclear factor k B and initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
20. Marui N, Offermann MK, Swerlick R, et al. Vascular adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-1874.
21. Ridker PM, Burning JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
22. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
23. Koh KK, Blum A, Hathaway L, et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation. 1999;100:1851-1857.
24. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol lowering therapies in hypercholesteromic women. Circulation. 1999;99:354-360.
25. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The PEPI study. Circulation. 1999;100:712-722.
26. Szanto E, Gruber D, Sator M, et al. Placebo-controlled study of melbrosia in treatment of climacteric symptoms. Wien Med Wochenschr. 1994;7:130-133.
27. Zung WW, Richards CB, Short MJ. Self-rating depression scale in an outpatient clinic. Arch Gen Psychiatry. 1965;13):508-515.
28. Zerssen D. Die Beschwerden-Liste. Manual. Weinheim, Germany: Beltz Test Gesellschaft; 1976.
29. Zerssen D. Typus melancholicus from a psychometric viewpoint. Z Klin Psychoter. 1976;24:200-220.
30. Deusinger IM. Measurement of change in self-concept with the Frankfurt self-concept scales. Z Gerontol. 1982;15:42-45.
31. Schumacher J, Braehler E. Testdiagnostik in der Psychoterapie in: Senf W, Broda M (eds). Praxis der Psychiterapie-ein integratives. Lehrbuch Stuttgart Thieme Verlag; 2000: 116-128.
32. Armitage P. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications; 1971: 189-207.
33. Siegal S, Castellan NJ Jr, Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw-Hill; 1988: 87-95.
34. Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-119.
35. Suvanto-Luukkonen E, Sudstrom H, Penttinen J, Laara E, Pramila S, Kauppila A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 1997;26:211-217.
36. Lopes P, Merkus H, Nauman J, Bruschi F, Fiodart J-M, Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol. 2000;96:906-912.
37. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: poison statement of the North American Menopause Society. Menopause. 2004;11:11-33.
38. Binder EF, Williams DB, Schechtman KB, Jeffe DB, Ko HT: Effects of hormone replacement therapy on serum lipids in elderly women: a randomized, placebo-controlled trial. Ann Intern Med. 2001;134:754-760.
39. Corti MC, Salive ME, Pahor M, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539-544.
40. Murkies AL, Wilcox G, Davis SR. Phytoestrogens. J Endocrinol Metab.1998;83:297-303.
41. Goudev A, Kyurkchiev S Gergova V, et al. Reduced concentrations of soluble adhesion molecules after antioxidant supplementation in postmenopausal women with high cardiovascular risk profiles a randomized double-blind study. Cardiology. 2000;94:227-232.